NYSE:FRX - Forest Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

Receive FRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNYSE:FRX
Previous Symbol
CUSIP34583810
Phone+1-212-4217850

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Forest Laboratories (NYSE:FRX) Frequently Asked Questions

What is Forest Laboratories' stock symbol?

Forest Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "FRX."

Has Forest Laboratories been receiving favorable news coverage?

Media stories about FRX stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Forest Laboratories earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned media coverage about the healthcare company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

How do I buy shares of Forest Laboratories?

Shares of FRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Forest Laboratories' official website?

The official website for Forest Laboratories is http://www.frx.com.

How can I contact Forest Laboratories?

Forest Laboratories' mailing address is 909 3rd Ave, NEW YORK, NY 10022-4731, United States. The healthcare company can be reached via phone at +1-212-4217850.


MarketBeat Community Rating for Forest Laboratories (NYSE FRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  281 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about Forest Laboratories and other stocks. Vote "Outperform" if you believe FRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Featured Article: SEC Filing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel